Base Year
Historical Year
Forecast Year
The autism spectrum disorder therapeutics market size attained a value of USD 2.11 billion in 2023, driven by the increasing research and development aided by the government and industrial players, and a growing pipeline of autism spectrum disorder drugs across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032 to attain a value of USD 3.56 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autism spectrum disorder (ASD) is a neurological development disability characterized by conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. This neurological and developmental disorder can begin in infancy and last throughout adulthood throughout a person’s life. It can be diagnosed based on behavioural patterns. ASD treatments are focused on reducing the factors that interfere with an individual’s orderly functioning. Some of the drugs approved by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.
The autism spectrum disorder therapeutics market is affected by the growing number of patients and the increasing awareness regarding the disease. The rising governmental initiatives are also expected to encourage research in this area. Further, rapid technological advancements in medicine are likely to favor market growth during the forecast period. Moreover, the adoption of behavioral therapies to overcome the communication gap in such patients is poised to aid the market expansion.
Rising Number of Pipeline Drugs Expected to Propel Market Growth
The forecast period is expected to witness rising development of drugs to treat autism spectrum disorder. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the market growth. For instance, in 2023, STALICLA, a Swiss clinical-stage biotech company announced the completion of the phase 1b trials for STP1. The trials will allow the application of the company’s precision medicine discovery platform in ASD. The increasing research and development activities associated with autism spectrum disorder are expected to result in the introduction of new and effective treatment options, which are set to elevate the market value.
Growth in Clinical Trials to Meet Rising Autism Spectrum Disorder Therapeutics Market Demand
In March 2024, a clinical-stage biopharmaceutical company based in Israel, SciSparc Ltd., announced the dosing of the first patient in the SCI-210 clinical trial, a randomized, controlled, double-blind clinical trial for pediatric patients with autism spectrum disorder. SCI-210 treatment is a combination of CannAmide™ (palmitoylethanolamide-based tablets) and cannabidiol-rich oil (CBD). The clinical trial, which will enroll 60 children, aims to assess the safety, efficacy, and tolerability of SCI-210 for the treatment of ASD in comparison to CBD monotherapy. The surge in clinical trials, supported by substantial investment from the leading pharmaceutical companies, is anticipated to significantly contribute to the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
| Key Trends | Impact |
| Advancement in Diagnostic Tools | The rising advancement in diagnostic tools and techniques that enable earlier detection of autism spectrum disorder is a major trend that stimulates the demand for the therapeutics market. Further, increased implementation of screening programs, particularly in schools and pediatric practices, is resulting in early diagnosis and timely intervention. |
| Development of Behavioral Therapies | The rising focus on the development of behavioral therapies is a major market trend. Behavioral therapies including applied behavior analysis (ABA) and cognitive-behavioral therapy (CBT) are increasingly being integrated into treatment plans and are poised to boost the autism spectrum disorder therapeutics market share. |
| Rising Adoption of Telemedicine and Digital Health Platforms | The market is experiencing a rising adoption of telemedicine and digital health platforms which has expanded access to care for individuals with autism spectrum disorder, particularly those living in underserved areas. The increasing remote access to care is expected to augment the market demand in the forecast period. |
| Increased Awareness Campaigns | Increased public campaigns and advocacy efforts are leading to greater acceptance of autism spectrum disorder, which is resulting in early diagnosis of the affected patients. In addition, advocacy groups and several foundations are offering considerable funding and support for ASD research and treatment development, which directly impacts the market dynamics. |
Market Breakup by Disease Type
Market Breakup by Treatment Type
Market Breakup by Age Group
Market Breakup by Route of Administration
Market Breakup by Region
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on treatment, the market is segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others. These medications help in treating different aspects associated with the disorder, ranging from managing core symptoms to treating comorbid conditions. The antipsychotic drugs segment covers a significant market share owing to their efficacy in managing severe behavioral issues such as aggression, irritability, and self-injurious behaviors, which are common in individuals affected by the condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to hold a significant share of the market during the forecast period, supported by the increased number of autism spectrum disorder cases in the region. The market is also supported by the presence of a favorable regulatory environment. For example, the United States Food and Drug Administration (FDA) authorized the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD) in 2021.
The region is also characterised by research and development in the field of autism spectrum disorder which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the United States, supports research focused on the treatment of autism spectrum disorder and related disorders.
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company AbbVie Inc. is involved in research and development (R&D) efforts to create medications for autism spectrum disorder. The company's robust portfolio of neurological and psychiatric therapeutics and its strong R&D capabilities position it as a significant player in the market.
Jazz Pharmaceuticals
This global biopharmaceutical company specializes in developing treatments in the neuroscience and oncology domain. Jazz Pharmaceuticals plays a crucial role in driving innovation and growth in the market by substantially investing in the clinical development of ASD therapeutics.
Novartis AG
Novartis AG, a Swiss multinational pharmaceutical corporation, significantly contributes to autism spectrum disorder therapeutics market growth, by participating in strategic collaborations to advance the understanding and treatment of ASD. Such partnerships also accelerate the development of effective therapies.
Johnson & Johnson Services, Inc.
Johnson & Johnson pharmaceutical drug division Johnson & Johnson Innovative Medicine heavily invests in research and development for neurological disorders including autism spectrum disorder. Its established portfolio of psychiatric medications makes it one of the leading players in the market.
Other key players in the market include Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Age Group |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share